Trial · NCT05626322
Results by group170
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 170
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) | PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide | 0 | Participants | ||
| Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) | PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide | 0 | Participants | ||
| Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) | PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide | 0 | Participants | ||
| Phase 1b: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide | 3 | Participants | ||
| Phase 1b: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide | 2 | Participants | ||
| Phase 1b: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide | 1 | Participants | ||
| Phase 1b: Number of Participants With Serious Treatment Emergent Adverse Events | PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide | 3 | Participants | ||
| Phase 1b: Number of Participants With Serious Treatment Emergent Adverse Events | PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide | 0 | Participants | ||
| Phase 1b: Number of Participants With Serious Treatment Emergent Adverse Events | PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide | 0 | Participants | ||
| Phase 1b: Number of Participants With Treatment-Related AEs | PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide | 3 | Participants | ||
| Phase 1b: Number of Participants With Treatment-Related AEs | PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide | 2 | Participants | ||
| Phase 1b: Number of Participants With Treatment-Related AEs | PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide | 1 | Participants | ||
| Phase 1b: Number of Participants With Grade Shift From Baseline in Hematology Parameters to Any Time Post-baseline | PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide | Anemia: Grade 1 to Grade 2 | 1 | Participants | |
| Phase 1b: Number of Participants With Grade Shift From Baseline in Hematology Parameters to Any Time Post-baseline | PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide | Anemia: Grade 1 to Grade 2 | 0 | Participants | |
| Phase 1b: Number of Participants With Grade Shift From Baseline in Hematology Parameters to Any Time Post-baseline | PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide | Anemia: Grade 1 to Grade 2 | 0 | Participants | |
| Phase 1b: Number of Participants With Grade Shift From Baseline in Hematology Parameters to Any Time Post-baseline | PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide | Anemia: Grade 2 to Grade 3 | 1 | Participants | |
| Phase 1b: Number of Participants With Grade Shift From Baseline in Hematology Parameters to Any Time Post-baseline | PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide | Anemia: Grade 2 to Grade 3 | 0 | Participants | |
| Phase 1b: Number of Participants With Grade Shift From Baseline in Hematology Parameters to Any Time Post-baseline | PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide | Anemia: Grade 2 to Grade 3 | 0 | Participants | |
| Phase 1b: Number of Participants With Grade Shift From Baseline in Hematology Parameters to Any Time Post-baseline | PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide | Leukocytosis: Grade 0 Grade 3 | 1 | Participants | |
| Phase 1b: Number of Participants With Grade Shift From Baseline in Hematology Parameters to Any Time Post-baseline | PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide | Leukocytosis: Grade 0 Grade 3 | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05626322/results